Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
30.09
-0.55 (-1.80%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
Today 9:45 EST
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at
February 27, 2026
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent
↗
February 25, 2026
The company said it has enrolled patients in its late-stage program ahead of schedule.
Via
Stocktwits
Topics
Earnings
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
February 25, 2026
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
February 25, 2026
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
February 23, 2026
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Present at Upcoming Investor Conferences
February 09, 2026
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics SVPs Engage In Heavy Transactions
↗
January 12, 2026
Multiple Senior Vice Presidents of this biotech company recently engaged in transactions that involved thousands of shares. What does this mean for the stock as it continues its long journey to regain...
Via
The Motley Fool
Topics
Regulatory Compliance
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
December 09, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?
↗
November 10, 2025
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government...
Via
Benzinga
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
November 10, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Present at Upcoming Investor Conferences
November 07, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
November 06, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
November 06, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
October 30, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
↗
October 13, 2025
Via
Benzinga
Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX)
↗
October 03, 2025
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level.
Via
Chartmill
5 Analysts Assess Celldex Therapeutics: What You Need To Know
↗
September 17, 2025
Via
Benzinga
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
September 17, 2025
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
September 09, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 08, 2025
Via
Benzinga
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
↗
August 20, 2025
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement.
Via
Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
↗
August 20, 2025
Via
Benzinga
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
August 20, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 20, 2025
Via
Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
↗
August 20, 2025
Via
Benzinga
Why Are Celldex Shares Tumbling After Hours?
↗
August 19, 2025
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit.
Via
Stocktwits
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 19, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
August 19, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
